Patents by Inventor Robert SABBAGH

Robert SABBAGH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinin-based theranostic probes for solid cancers and uses thereof
    Patent number: 11213597
    Abstract: It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 4, 2022
    Assignee: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Fernand Gobeil, Brigitte Guerin, Martin Lepage, Robert Sabbagh, David Fortin
  • ONCOGENIC ALTERNATIVE SPLICING SWITCH OF PACE4 IN CANCER
    Publication number: 20190316211
    Abstract: It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also provided a method treating a cancer in a patient comprising administering an inhibitor of PACE4-altCT to a patient in need thereof and a kit comprising an analyte specific reagent specifically binding to PACE4-altCT for detecting a cancer.
    Type: Application
    Filed: November 29, 2017
    Publication date: October 17, 2019
    Applicant: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINE
    Inventors: Robert DAY, Frédéric COUTURE, Robert SABBAGH
  • NOVEL KININ-BASED THERANOSTIC PROBES FOR SOLID CANCERS AND USES THEREOF
    Publication number: 20180311385
    Abstract: It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.
    Type: Application
    Filed: June 23, 2016
    Publication date: November 1, 2018
    Inventors: Fernand GOBEIL, Brigitte GUERIN, Martin LEPAGE, Robert SABBAGH, David FORTIN